- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04891640
Reducción biológica y captura de los resultados de los niños y la frecuencia de los brotes en la espondiloartritis juvenil (BACK-OFF JSpA)
Reducción biológica y captura de los resultados de los niños y la frecuencia de brotes en la espondiloartritis juvenil (BACK-OFF JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1E8
- The Hospital for Sick Children
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Phoenix Children's
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Children's Hospital Los Angeles
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington, Delaware, Estados Unidos, 19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Children's National Health System
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Children's Mercy Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Hospital for Special Surgery
-
Queens, New York, Estados Unidos, 11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44302
- Akron Children's Hospital
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern Medical Center
-
Houston, Texas, Estados Unidos, 77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Seattle Children's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
Experimental: TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
Experimental: TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
Periodo de tiempo: 12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
Periodo de tiempo: 12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 21-018442
- : GRT-00001036 (Otro número de subvención/financiamiento: PCORI)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .